Drug Approval | December 28, 2021
Optimus Pharma to manufacture and market molnupiravir
The company has developed the API in house at its R&D center in Hyderabad
The company has developed the API in house at its R&D center in Hyderabad
All the recommendations have been sent to the Drugs Controller General of India (DCGI) for final approval.
It plans to deliver over 300 million doses to the Indian government
DCGI approved the drug based on the review of clinical data
Molnupiravir is an orally administered form of a potent ribonucleoside analog that inhibits the replication of SARS-CoV-2
The drug will be marketed under the brand name Molnaflu
The Covid-19 At-Home Test uses a simple nasal swab sample to enable individuals to self-test at home and receive accurate, reliable and quick results in as few as 20 minutes for SARS-CoV-2 and all known variants of concern, including Omicron
The Home Healthcare market is expected to be US $ 14.2 by 2025
Sucharita brings with her a rich and varied experience of two decades in Information Technology and Financial Services
Systemic Lupus Erythematosus, or Lupus, is an autoimmune chronic inflammatory disease. The prevalence of SLE in the U.S. has been reported to be between 20 to 150 cases per 100,000. In India, the reported prevalence of SLE is 3.2 per 100,000
Subscribe To Our Newsletter & Stay Updated
